Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

CureVac AG. (5/2/17). "Press Release: CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary". Tübingen.

Organisation Organisation CureVac Inc.
  Group CureVac (Group)
Products Product RNA-based therapeutic
  Product 2 RNActive® vaccination technology
Persons Person Menichella, Daniel (CureVac 201705– CEO of CureVac Inc before Bamboo Therapeutics + Applied Genetic Technologies)
  Person 2 Hoerr, Ingmar (CureVac 200601 CEO + co-founder)
     


CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, today announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston based U.S. subsidiary. Mr. Menichella, an experienced executive in the biotech-industry, will develop CureVac’s US organization with a clear focus on business and corporate development activities around CureVac’s versatile mRNA technology platform.

Established in 2015, CureVac Inc. provides a US base of operations for CureVac AG to capitalize on its numerous research and business initiatives as the Company advances its pipeline of mRNA therapeutics targeting oncology and infectious diseases, as well as molecular therapies designed to trigger the body's own production of therapeutic proteins. In this regard, Mr. Menichella and his team will be responsible for maximizing the value of these technologies by enabling CureVac to more directly engage pharmaceutical communities, particularly those in the US.

“As CEO of CureVac Inc., my goal will be to expand CureVac’s US business entity and to focus the corporate development efforts to grow our business globally,” said Mr. Menichella. “CureVac has established the most diverse and advanced development platform in the mRNA industry. I am convinced that the company is in the best position to bring the first mRNA product to the market. There have been many exciting developments at CureVac and I look forward to playing an instrumental role in advancing the company further.”

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac AG, stated, “It is a great pleasure to welcome Dan on board. We look forward to benefiting from his vast expertise as we expand our operations in the US and strengthen our business development efforts.”

Mr. Menichella has held a variety of corporate and business development roles for a number of leading companies during his career, including Bamboo Therapeutics, Applied Genetic Technologies Corp., Zyngenia Inc., Talecris Biotherapeutics Holdings Corp. and Merck KGaA. In these roles, Mr. Menichella led major M&A and licensing deals, corporate strategy and commercialization activities.


About CureVac AG

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical Company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies this for the development of cancer therapies, prophylactic vaccines and molecular therapies.

Since its inception, strongly backed by SAP founder Dietmar Hopp’s dievini CureVac has received approximately $370 million (€355 million) in equity investments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment of an industrial scale production.

For more information, please visit www.curevac.com.

***


Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756
communications@curevac.com

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694
amielach@tiberend.com

   
Record changed: 2017-06-07

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px